Positron (OTCMKTS:POSC – Get Free Report) is one of 70 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Positron to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.
Profitability
This table compares Positron and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Positron | -300.00% | N/A | -89.57% |
Positron Competitors | -350.61% | -97.06% | -31.48% |
Earnings and Valuation
This table compares Positron and its competitors revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Positron | $740,000.00 | -$1.64 million | -12.00 |
Positron Competitors | $1.06 billion | $91.09 million | 87.01 |
Insider and Institutional Ownership
44.2% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 13.9% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations for Positron and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Positron | 0 | 0 | 0 | 0 | N/A |
Positron Competitors | 259 | 780 | 1923 | 59 | 2.59 |
As a group, “Electromedical equipment” companies have a potential upside of 3,163.72%. Given Positron’s competitors higher possible upside, analysts plainly believe Positron has less favorable growth aspects than its competitors.
Risk and Volatility
Positron has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s competitors have a beta of 0.99, indicating that their average stock price is 1% less volatile than the S&P 500.
Summary
Positron competitors beat Positron on 6 of the 9 factors compared.
About Positron
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.